Kamada
- Country
- 🇮🇱Israel
- Ownership
- -
- Employees
- 378
- Market Cap
- $326M
- Introduction
Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties. The company was founded by David Tsur and Ralf Hahn on December 13, 1990 and is headquartered in Rehovot, Israel.
Clinical Trials
11
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19
- Conditions
- Pneumonia, ViralCovid19
- First Posted Date
- 2020-09-16
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Kamada, Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT04550325
- Locations
- 🇮🇱
Wolfson Medical Center, Holon, Israel
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Sheba Medical Center Hospital- Tel Hashomer, Ramat Gan, Israel
Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation"
- Conditions
- Alpha 1-Antitrypsin Deficiency
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2025-01-17
- Lead Sponsor
- Kamada, Ltd.
- Target Recruit Count
- 220
- Registration Number
- NCT04204252
- Locations
- 🇬🇧
Royal Infirmary of Edinburgh, Edinburgh, United Kingdom
🇬🇧University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
🇧🇪University Hospital (UZ) Leuven, Leuven, Belgium
Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies
- First Posted Date
- 2016-09-23
- Last Posted Date
- 2021-09-05
- Lead Sponsor
- Kamada, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02912845
- Locations
- 🇺🇸
ACH, Little Rock, Arkansas, United States
Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation
- Conditions
- Transplantation, Lung Rejection
- Interventions
- First Posted Date
- 2015-11-25
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Kamada, Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT02614872
- Locations
- 🇮🇱
Pulmonary Institute - Rabin Medical Center, Petach Tikva, Israel
Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
- Conditions
- Rabies
- Interventions
- Drug: Active rabies vaccine (US-FDA approved)
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2021-09-29
- Lead Sponsor
- Kamada, Ltd.
- Target Recruit Count
- 118
- Registration Number
- NCT02040090
- Locations
- 🇺🇸
Prism Research Inc, Saint Paul, Minnesota, United States
- Prev
- 1
- 2
- 3
- Next
News
CMV Treatment Pipeline Expands with 20+ Therapies from Leading Pharmaceutical Companies
DelveInsight's 2025 assessment reveals 15+ companies are developing over 20 cytomegalovirus (CMV) infection treatment therapies across various clinical development phases.
Kamada Announces Reduced Sample Size for Inhaled AAT Phase 3 Trial Following FDA Feedback
Kamada anticipates achieving its 2024 financial goals, projecting revenues between $158 million and $162 million and adjusted EBITDA between $32 million and $35 million.